Revolutionizing Brain Cancer Treatment: A Strategic Alliance in Healthcare

Carthera Collaborates with Accord Healthcare to Advance Treatment of Glioblastoma

2 mins read
doctor looking at ct scan result
Photo by Tima Miroshnichenko on Pexels.com

Key Takeaways:

  • Strategic Collaboration: Carthera partners with Accord Healthcare for the development and supply of carboplatin.
  • Innovative Medical Device: SonoCloud®, an ultrasound-based device, poised to transform the treatment of recurrent glioblastoma.
  • Focus on Patient Outcomes: This partnership aims to facilitate regulatory approval, ensuring carboplatin’s supply for trials and future commercialization.

A Milestone in Brain Disorder Treatment

Paris, France, November 6, 2023 – Carthera, an innovative medtech company born from Sorbonne University, has announced a strategic collaboration with Accord Healthcare Limited, a leading pharmaceutical company. This partnership is set to enhance the development, manufacturing, and commercialization of carboplatin in conjunction with Carthera’s groundbreaking SonoCloud® system for treating recurrent glioblastoma (rGBM), a severe form of brain cancer.

Carthera’s SonoCloud®: Pioneering in Brain Health

Transforming Glioblastoma Treatment

Carthera’s SonoCloud® represents a major advancement in the field of brain disorders. This proprietary implantable device is designed to open the Blood-Brain Barrier (BBB) using low-intensity pulsed ultrasound (LIPU), facilitating effective chemotherapy delivery to brain tumors. This novel approach has the potential to significantly improve treatment efficacy for glioblastoma, a disease with a median survival rate of around 15 months post-diagnosis.

See also  Unleashing the Power of Electrification: How a Revolutionary Kit is Changing the E-Bike Game

The Collaboration’s Impact

Enhancing Carboplatin’s Role

The partnership between Carthera and Accord Healthcare involves the development and supply of carboplatin, a crucial component in the SonoCloud solution for rGBM treatment. By securing the supply of carboplatin, this collaboration strengthens the SonoCloud system’s profile, aiding in the regulatory approval process and ensuring its availability for future trials and commercialization.

A Synergistic Approach to Innovation

Shared Vision for Better Health Outcomes

Accelerating Market Authorization

Frédéric Sottilini, CEO of Carthera, expresses enthusiasm about the collaboration with Accord Healthcare. He underscores their mutual commitment to advancing SonoCloud technology and improving outcomes for patients with glioblastoma. The partnership is aimed at bolstering their chances of obtaining marketing authorization for SonoCloud in the upcoming years.

Accord Healthcare’s Contribution

Expanding Carboplatin Applications

Alex Falgas, VP Business Development & Portfolio, Europe & MENA at Accord Healthcare, highlights the significance of extending their carboplatin franchise to glioblastoma treatment. This collaboration aligns with Accord’s dedication to supplying innovative products and enhancing patient outcomes, particularly for diseases with high unmet medical needs.

About SonoCloud®

A Breakthrough in Medical Technology

SonoCloud is an innovative medical device developed by Carthera. It employs ultrasound to temporarily increase the permeability of blood vessels in the brain, thereby enhancing the delivery of therapeutic molecules. The device, invented by Pr. Alexandre Carpentier and developed in collaboration with LabTAU, INSERM in Lyon, France, represents a potential new treatment option for various brain conditions, including tumors and Alzheimer’s disease. The safety and approval of SonoCloud for investigational use are currently under review by regulatory authorities.

See also  Shocking Revelation: 1 in 5 Workers Flee Offices to Escape Irritating Colleagues

About Accord Healthcare Ltd

A Leader in Pharmaceutical Innovation

Headquartered in the UK, Accord Healthcare Ltd. is among the fastest-growing pharmaceutical companies in Europe. With a significant presence in the oncology sector and a commitment to improving product access, Accord is shaping the future of healthcare. Their portfolio includes over 40 oncology treatments and plans to introduce 20 more in the next five years.

About Carthera

Advancing Ultrasound-Based Medical Devices

Carthera, a spin-off from AP-HP Paris and Sorbonne University, is a clinical-stage medtech company focusing on developing ultrasound-based medical devices for brain disorders. Founded in 2010, Carthera has received support from various national and international agencies, reflecting its commitment to innovative healthcare solutions.


Sign up to our newsletter & get the most important monthly insights from around the world.


Ready to Amplify Your Brand with Business Today?

Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!

Click here to explore our Promotion & Sponsored Articles page.

Are you looking to make an impact? Contact us at [email protected] to get started!

See also  Turbostart Invests 3 Crores in Invincible Ocean to Drive Digital Onboarding Innovation

Business Today News

BusinessToday.news is an online publication committed to delivering comprehensive and insightful coverage of the latest business news, trends, and practices. With a focus on finance, technology, entrepreneurship, and other critical areas, it serves as a valuable resource for professionals seeking to stay abreast of the rapidly evolving business landscape.

Leave a Reply

Your email address will not be published.

Latest from Blog

About

BusinessToday.news is a premier online platform dedicated to providing the latest news and insights on a wide range of topics related to the business world, including technology, finance, real estate, healthcare, and more.

Newsletter

Copyright Unstructured.Media. All rights reserved. Explore our sitemap